Entropy NeurodynamicsTYPTF -45.63% Quick Ratio is 7.78 as of Dec. 2025, which is at its 10-year median of 7.78. The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Entropy Neurodynamics ranks better than 72.18% on this metric.
Entropy Neurodynamics has a quick ratio of 7.78. It generally indicates good short-term financial strength.
The historical rank and industry rank for Entropy Neurodynamics's Quick Ratio or its related term are showing as below:
TYPTF'
s Quick Ratio Range Over the Past 10 Years
Min: 1.62 Med: 7.78 Max: 96.7
Current: 7.78
During the past 7 years, Entropy Neurodynamics's highest Quick Ratio was 96.70. The lowest was 1.62. And the median was 7.78.
TYPTF's Quick Ratio is ranked better than 72.18% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs TYPTF: 7.78
Entropy Neurodynamics (OTCPK:TYPTF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Entropy Neurodynamics Quick Ratio Related Terms
Entropy Neurodynamics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Entropy Neurodynamics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entropy Neurodynamics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Entropy Neurodynamics's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics (TYPTF) has a Quick Ratio of 7.78 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Entropy Neurodynamics and its competitors. This is near median its historical median of 7.78. Over the past decade, Entropy Neurodynamics' Quick Ratio has ranged from 1.62 to 96.70. According to the industry distribution chart, Entropy Neurodynamics ranks #394 out of 1416 companies in the Biotechnology industry, placing it in the top 27.8%.
Is Entropy Neurodynamics' Quick Ratio too high?
Entropy Neurodynamics' current Quick Ratio of 7.78 is near median its 10-year median of 7.78. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 96.70. The Biotechnology industry median Quick Ratio is 3.60. Entropy Neurodynamics' value of 7.78 is 116.1% above this industry median. Based on the distribution chart, Entropy Neurodynamics ranks #394 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entropy Neurodynamics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #394 out of 1416 companies for Quick Ratio. This puts Entropy Neurodynamics in the upper half of its industry. The industry median Quick Ratio is 3.60. Entropy Neurodynamics' value of 7.78 is 116.1% above this benchmark. Historically, Entropy Neurodynamics' own Quick Ratio has ranged from 1.62 to 96.70 over the past decade. While the company's 10-year median is 7.78 vs. the industry median of 3.60, Entropy Neurodynamics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entropy Neurodynamics's current Quick Ratio of 7.78 is 116.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Entropy Neurodynamics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current Quick Ratio is 7.78, which is near median its own 10-year median of 7.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12% above its estimated fair value. The current Quick Ratio is 7.78, which is near median its 10-year median of 7.78 and 116.1% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Quick Ratio is 7.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 